



JURATA
THIN FILM



Revolutionizing Biologics Manufacturing, Storage, & Distribution

Megan Livingston
Senior Director, Business Development
mlivingston@juratatf.com

MBB Symposium
June 12, 2023



Covid-19 illuminated the shortcomings of pharmaceutical supply chain in low-resource settings...

... Jurata's thin film technology addresses these shortcomings by expediting manufacturing, removing cold chain requirements, and enabling needle-free delivery

Thin Film Manufacturing Process



Receive API

Purify the API to remove salt and other excipients from API bulk, if necessary



Mix Thin Film Formulation & API

Stir thin film base and bulk API at appropriate concentration



Dispense Into Molds

Dispense solution into 1 mL thin film molds (1 dose)



Dry Under Airflow

Dry under room temperature airflow for ~2.5 hours



Package & Ship


Heat seal lidding
Add to secondary containment, add label, & ship



Thin Film-Stabilized Vaccine Confers Life-Saving Protection Against Ebola

A 50% dose of vaccine stabilized in Jurata's thin film technology, then reconstituted and administered as nasal spray provided 100% survival to non-human primates injected with lethal dose of Ebola

Equivalent dosage of frozen vaccine only conferred 50% survival when administered IM and ~65% survival when administered as a nasal spray



Choi, J.H. et al. *Mol. Pharm.*, 2015.12(8): 2712-2731

Our Clients / Partners Have...

Monoclonal Antibodies

Vaccines

Cytokines

Proteins

Gene Therapy

Plasmids



And Want to...

Remove Cold Chain

Avoid Lyophilization

Manufacture 6.5X Cheaper & up
to 20X Faster

Change Administration Routes

Our Thin Film Technology Enables...

Regional fill/finish manufacturing

Shipping without temperature control

3-year room temperature storage

Needle-free delivery